Sun Pharma to Present ILUMYA, LEQSELVI, WINLEVI Data at AAD 2026, Showcases Dermatology Advances

The company stated that the presentations, scheduled between March 27 and March 31, 2026, in Denver, Colorado, demonstrate its continued leadership in dermatology and immunology, with a focus on delivering safe and effective treatments for chronic skin conditions.

Among the key highlights, data on ILUMYA (tildrakizumab) showcased sustained efficacy and safety in patients with moderate-to-severe psoriasis, including those with nail involvement, over a 52-week period. Real-world evidence further indicated that the therapy provides long-term disease control across diverse patient populations globally.

In alopecia areata, pooled results from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials of LEQSELVI (deuruxolitinib) demonstrated significant scalp hair regrowth as early as Week 8 and Week 12, with continued improvement over time. Additionally, survey findings revealed gaps between patient and clinician perspectives regarding disease burden and treatment expectations, highlighting the need for improved communication and patient-centered care.

For acne treatment, findings from a 52-week study of WINLEVI (clascoterone cream 1%) showed notable reductions in facial sebum production and acne severity. Combination therapy studies also suggested broader clinical utility of the treatment in multimodal acne management.

The company will also provide interactive engagement opportunities for clinicians at its exhibition booth during the event, enabling participants to explore its dermatology and immunology portfolio in detail.

Sun Pharma emphasized that these presentations reinforce its commitment to advancing scientific research and improving clinical outcomes for patients with chronic dermatological conditions. The data spans clinical trials, real-world evidence, and patient-centered research approaches.

Sun Pharmaceutical Industries Limited, headquartered in India, is one of the world’s leading specialty generics companies with a strong presence across dermatology, ophthalmology, and specialty therapies, with operations in over 100 countries.